Ken Griffin Nuvation Bio Inc. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 5,532,976 shares of NUVB stock, worth $12.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,532,976

Previous 4,600 120182.09%

Holding current value

$12.8 Million

Previous $8,000 134762.5%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.66 - $2.53 $5.69 Million - $8.67 Million	3,427,130 Added 162.74%	5,532,976 $10.8 Million
Q1 2025 May 15, 2025	SELL	$1.76 - $3.25 $126,924 - $234,377	-72,116 Reduced 3.31%	2,105,846 $3.71 Million
Q4 2024 Feb 14, 2025	SELL	$2.01 - $3.01 $1.17 Million - $1.75 Million	-580,397 Reduced 21.04%	2,177,962 $5.79 Million
Q3 2024 Nov 14, 2024	BUY	$2.3 - $3.83 $1.75 Million - $2.92 Million	762,142 Added 38.18%	2,758,359 $6.34 Million
Q2 2024 Aug 14, 2024	SELL	$2.58 - $3.69 $266,715 - $381,464	-103,378 Reduced 4.92%	1,996,217 $5.83 Million
Q1 2024 May 15, 2024	SELL	$1.46 - $3.97 $1.28 Million - $3.48 Million	-877,707 Reduced 29.48%	2,099,595 $7.64 Million
Q4 2023 Feb 14, 2024	BUY	$0.96 - $1.53 $506,348 - $806,992	527,446 Added 21.53%	2,977,302 $4.5 Million
Q3 2023 Nov 14, 2023	BUY	$1.26 - $2.1 $48,100 - $80,167	38,175 Added 1.58%	2,449,856 $3.28 Million
Q2 2023 Aug 14, 2023	SELL	$1.56 - $1.84 $699,174 - $824,667	-448,189 Reduced 15.67%	2,411,681 $4.34 Million
Q1 2023 May 15, 2023	SELL	$1.6 - $2.48 $3.93 Million - $6.09 Million	-2,455,161 Reduced 46.19%	2,859,870 $4.75 Million
Q4 2022 Feb 14, 2023	SELL	$1.68 - $2.5 $552,239 - $821,785	-328,714 Reduced 5.82%	5,315,031 $10.2 Million
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $6,237 - $86,900	21,510 Added 0.38%	5,643,745 $12.6 Million

Others Institutions Holding NUVB

# of Institutions

193

Shares Held

168M

Call Options Held

2.31M

Put Options Held

221K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $504M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account